Granted Patent
B2
US 12,433,846 · App. 17/484,725 · Granted Oct 7, 2025
Drug delivery system for treatment of cancer
Inventors:
Yrr Morch (Trondheim, NO); Ruth Schmid (Tiller, NO); Einar Sulheim (Trondheim, NO); Per Stenstad (Trondheim, NO); Heidi Johnsen (Trondheim, NO); Kjersti Flatmark (Blommenholm, NO); Karianne Giller Fleten (Oslo, NO)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Described herein is a hydrophobic anti-cancer drug encapsulated into poly(alkyl cyanoacrylate) nanoparticles and their use in cancer treatments by intracavitary rout of administration such as intraperitoneal administration.
Claims (11)
1. A method for treatment of cancer in a subject, the method comprising intraperitoneally administering to the subject a poly(alkyl cyanoacrylate) nanoparticle, the nanoparticle encapsulating a hydrophobic anti-cancer drug, and wherein the nanoparticle is administered to the subject to treat the cancer in the subject, wherein the poly(alkyl cyanoacrylate) comprises a cyanoacrylate having a 2-ethyl butyl (EBCA) alkyl chain, wherein the nanoparticle does not include a targeting moiety, and wherein the cancer is a primary peritoneal cancer or peritoneal carcinomatosis.
2. The method of claim 1 , wherein the method comprises inhibiting metastasis in the subject.
3. The method of claim 1 , wherein the nanoparticle is produced according to a miniemulsion anionic polymerization process.
4. The method of claim 3 , wherein the nanoparticle has dimensions below 800 nm.
5. The method of claim 3 , wherein the nanoparticle has dimensions from 30 nm to 500 nm.
6. The method of claim 3 , wherein the nanoparticle is PEGylated.
7. The method of claim 1 , wherein the hydrophobic anti-cancer drug comprises 1-90 wt % of the total weight of the nanoparticle.
8. The method of claim 1 , wherein the hydrophobic anti-cancer drug is a taxane.
9. The method of claim 8 , wherein the taxane is cabazitaxel.
10. The method of claim 1 , wherein the cancer is pseudomyxoma peritonei or peritoneal carcinomatosis originating from ovarian cancer, colorectal carcinoma, gastric cancer, renal cancer, rectal carcinoma, pancreatic carcinoma, hepatocellular carcinoma, gallbladder carcinoma, appendiceal malignancies, endometrial carcinoma, cervical cancers, breast cancer, lung cancer, malignant melanoma, adrenocortical carcinoma, or transitional cell carcinoma of the urinary tract.
11. The method of claim 10 , wherein the subject is a human subject.
Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 060603 FRAME: 0181. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT.
Recorded Mar 29, 2023
From: SINTEF TTO AS
To: SINTEF TTO AS; OSLO UNIVERSITETSSYKEHUS HF
Reel/Frame 063189/0366 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 25, 2022
From: SINTEF TTO AS
To: OSLO UNIVERSITETSSYKEHUS HF
Reel/Frame 060603/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 21, 2022
From: MORCH, YRR; SULHEIM, EINHAR; FLATMARK, KJERSTI; FLETEN, KARIANNE GILLER; STENSTAD, PER; JOHNSEN, HEIDI; SCHMID, RUTH
To: SINTEF TTO AS
Reel/Frame 060576/0193 →
Continuity (3)
Continuation
PCTEP2019076121
· Sep 26, 2019
References Cited (60)
US 20100015165A1
· Landfester et al.
· 2010
[cited by applicant]
US 20200023073A1
· Morch et al.
· 2020
[cited by applicant]
US 20200061019A1
· Morch et al.
· 2020
[cited by applicant]
US 20210113482A1
· Morch et al.
· 2021
[cited by applicant]
CN 107115532A
· 2017
[cited by applicant]
EP 2508207A1
· 2012
[cited by applicant]
EP 2913065A1
· 2015
[cited by applicant]
NO 342271B1
· 2018
[cited by applicant]
WO 2006016020A2
· 2006
[cited by applicant]
WO 2006127953A2
· 2006
[cited by applicant]
WO 2008003706A1
· 2008
[cited by applicant]
WO 2014191502A1
· 2014
[cited by applicant]
WO 2016083533A1
· 2016
[cited by applicant]
WO 2016134115A1
· 2016
[cited by applicant]
WO 2017143967A1
· 2017
[cited by applicant]
WO 2017204475A1
· 2017
[cited by applicant]
WO 2018060437A1
· 2018
[cited by applicant]
Bensaid et al.; “Y-Shaped mPEG-PLA Cabazitaxel Conjugates: Well-Controlled Synthesis by Organocatalytic Approach and Self-Assembly into Interface Drug-Loaded Core-Corona Nanoparticles”; Biomacromolecules, vol. 14; 2013;…
[cited by applicant]
Burns, B.; “Polycyanoacrylates”; Encyclopedia of Polymer Science and Technology; John Wiley & Sons, Inc.; 2016; DOI: 10.1002/0471440264.pst256.pub2.
[cited by applicant]
Crespy, D. et al.; “Miniemulsion polymerization as a versatile tool for the synthesis of functionalized polymers”; Beilstein Journal of Organic Chemistry, vol. 6; 2010; pp. 1132-1148; doi: 10.3762/bjoc.6.130.
[cited by applicant]
Daisuke et al.; “Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis”; Gastric Cancer, vol. 20, Issue No. 1; 2016; pp. 111-121.
[cited by applicant]
Flatmark et al., “Exploring the peritoneal surface malignancy phenotype—a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models,” Human Pathology, 2010, vol. 41(8), pp. 1109-1119.
[cited by applicant]
Flatmark et al., “Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies,” International Journal of Cancer, 2013, vol. 133(6) pp. 1497…
[cited by applicant]
Flatmark et al., “Pseudomyxoma peritonei-two novel orthotopic mouse models portray the PMCA-I histopathologic subtype,” BMC Cancer, 2007, vol. 7:116, pp. 1-7.
[cited by applicant]
Fusser et al.; “Cabazitaxel-loaded Poly(2-ethylbutyl cyanocrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft”; Journal of Controlled Release, vol. 293; 2018; pp. 190-192.
[cited by applicant]
Hallaj-Nezhadi et al.; “Intraperitoneal delivery of nanoparticles for cancer gene therapy”; Future Oncology, vol. 9, Issue No. 1; 2013; pp. 59-68.
[cited by applicant]
International Preliminary Report on Patentability; International Application No. PCT/EP2017/074798; International Filing Date Sep. 29, 2017; Date of Mailing Aug. 21, 2018; 17 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2019/057678; International Filing Date Mar. 27, 2019; Date of Mailing, Jun. 25, 2019; 14 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application PCT/EP2019/076121; International Filing Date Sep. 26, 2019; date of Mailing Jan. 2, 2020; 12 pages.
[cited by applicant]
International Search Report and Written Opinion, International Application No. PCT/EP2017/074798; International Filing Date Sep. 29, 2017, Date of Mailing Jan. 12, 2017; 9 pages.
[cited by applicant]
Kamei et al.; “Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) in peritoneal metastatic modules”; Ca…
[cited by applicant]
Kumari et al., “Biodegradable polymeric nanoparticles based drug delivery systems,” Colloids and Surfaces B: Biointerfaces, 2010, vol. 75, pp. 1-18.
[cited by applicant]
Lu et al.; “Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting”; Cancer Chemotherapy and Pharmacology, vol. 59, Issue No. 2; 2006; pp. 175-181.
[cited by applicant]
Matsumura et al., “A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs,” Cancer Research, 1986, vol. 46 (12 Pt 1), pp. …
[cited by applicant]
Peracchia et al., “Development of sterically stabalized poly(isobutyl 2-cyanoacrylate) nanoparticles by chemical coupling of poly(ethylene glycol),” Journal of Biomedical Materials Research, 1997, vol. 34, pp. 317-326.
[cited by applicant]
Petrillo et al.; “Cytoreductive Surgery Plus Platinum-Based Hyperthermic Intraperitoneal Chemotherapy in Epithelial Ovarian Cancer: A Promising Integrated Approach to Improve Locoregional Control”; Oncologist, vol. 21, …
[cited by applicant]
Prabhakar et al., “Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology,” Cancer Research, 2013, vol. 73 (8), pp. 2412-2417.
[cited by applicant]
Shi et al., “Cancer nanomedicine: progress, challenges and opportunities,” Nat Rev Cancer, 2017, vol. 17 (1), pp. 20-37.
[cited by applicant]
Snipstad et al., “Ultrasound Improves the Delivery and Therapeutic Effect of Nanoparticle-Stabilized Microbubbles in Breast Cancer Xenografts,” Ultrasound Med Biol., 2017, vol. 43 (11), 2651-2669.
[cited by applicant]
Sulheim et al., “Cellular uptake and intracellular degradation of poly(alkyl cyanoacrylate) nanoparticles,” Journal of Nanobiotechnology, 2016, vol. 14 (1), pp. 1-14.
[cited by applicant]
Sulheim et al., “Cytotoxicity of Poly(Alkyl Cyanoacrylate) Nanoparticles,” International Journal of Molecular Sciences, 2017, vol. 18., 2454, pp. 1-17.
[cited by applicant]
Torchilin et al., “Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery,” Nat. Rev. Drug Discov, 2014, vol. 13 (11), pp. 813-827.
[cited by applicant]
Tsao et al.; “The Rose of Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer”; The Adv Urol; 6(3); pp. 97-104; (2014).
[cited by applicant]
Vrignaud et al., “Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors,” Clinical Cancer Research, 2013, vol. 19 (11), pp. 2973-2983.
[cited by applicant]
Zhang et al., “Preparation, characterization and biocompatibility of poly(ethylene glycol)-poly(n-butyl cyanoacrylate) nanocapsules with oil core via miniemulsion polymerization,” European Polymer Journal, 2008, vol. 44…
[cited by applicant]
Dieras, V. et al.; “Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study”; European Journal of Cancer, vol. 49; 2013; pp. 25-34; DOI: http://dx.doi.org/10.1016/j.ejca.2012.…
[cited by applicant]
Hekmatara, T. et al.; “Encapsulation of Water-Insoluble Drugs in Poly(butyl cyanoacrylate) Nanoparticles”; Journal of Nanoscience and Nanotechnology, vol. 9; 2009; pp. 5091-5098; DOI: 10.1166/jnn.2009.GR05.
[cited by applicant]
Hu, X.; “Docetaxel-Loaded Cholesterol-PEG Co-Modified Poly (n-Butyl) Cyanoacrylate Nanoparticles for Antitumor Drug Pulmonary Delivery: Preparation, Characterization, and in vivo Evaluation”; International Journal of Na…
[cited by applicant]
Huang, C.; “Synthesis of high loading and encapsulation efficient paclitaxel-loaded poly(n-butyl cyanoacrylate) nanoparticles via miniemulsion”; International Journal of Pharmaceutics, vol. 338; 2007; pp. 267-275.
[cited by applicant]
Dakwar, G. et al.; “Nanomedicine-based intraperitoneal therapy for the treatment of preitoneal carcinomatosis—Mission possible?” Advanced Drug Delivery Reviews, vol. 108; 2017; pp. 13-24.
[cited by applicant]
Vrignaud, P. et al.; “Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors”; Clinical Cancer Research, vol. 19, Issue No. 11; 2013; pp. 2973-2983.
[cited by applicant]
Yordanov, G.; “Poly(alkyl cyanoacrylate) nanoparticles as drug carriers: 33 years later”; Bulgarian Journal of Chemistry, vol. 1, Issue No. 2; 2012; pp. 61-73.
[cited by applicant]
Zhao, Li, et al. Nanoparticles and photodynamic therapy applied to ovarian cancer, Prog. Obstet Gynecol. 24(1), 2015, 11-13, English abstract.
[cited by applicant]